MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain

Journal of Neuro-Oncology

Volumn 77, Issue 1, 2006, Pages 95-103

  Wu, Genevieve N ^a   Ford, Judith M ^a,b   Alger, Jeffry R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Glioblastoma multiforme; Magnetic resonance imaging; Motexafin gadolinium; Radiation therapy

Indexed keywords

GADOLINIUM TEXAPHYRIN;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DOSE REGIMEN; DRUG PENETRATION; DRUG RETENTION; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; HUMAN; MAINTENANCE THERAPY; MALE; MATHEMATICAL COMPUTING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; COHORT STUDIES; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METALLOPORPHYRINS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE;

EID: 33745055840     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-9101-1     Document Type: Article

References (38)

1. Ohgaki H, Kleihues P 2005 Epidemiology and etiology of gliomas Acta Neuropathol 109:93-108
2. Curran WJ, Scott CB, Horton J, et al. 1993 Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials J Nat Cancer Inst 85: 704-710
3. Simpson JR, Horton J, Scott C, et al. 1993 Influence of location and extend of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trails Int J Radiat Oncol Biol Phys 26(2): 239-244
4. Walker MD, Alexander E, Jr., Hunt WE, et al. 1978 Evaluation of BCNU and/ or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trialJ Neurosurg 49:333-343
5. Walker MD, Strike TA, Sheline GE 1979 An analysis of dose-effect relationship in the radiotherapy of malignant gliomas Int J Radiat Oncol Biol Phys 5:1725-1731
6. Steward LA, 2002 Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trialsLancet 359: 1011-1018
7. Stupp R, Dietrich PY, Ostermann KS, et al. 2002: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20(5): 1375-1382
8. Brada M, Hoang-Xuan K, Rampling R, et al. 2001 Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapseAnn Oncol 12(2): 259-266
9. Lanzetta G, Campanella C, Rozzi A, et al. 2003 Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: Phase II clinical trial Anticancer Res. 23(6D):5159-5164
10. Daumas-Duport C, Scheithauer BW, Kelly PJ 1987 A histologic and cytologic method for the spatial definition of gliomas Mayo Clin Proc 62: 435-449
11. Earnest F IV, Kelly PJ, Scheithauer BW, et al. 1988 Cerebral astrocytomas: Histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166(3): 823-827
12. Sessler JL, Murai T, Hemmi G 1989 A water-stable Gadolinium (III) complex derived from a new pentadentate "expanded porphyrin" ligand Inorg Chem 28: 3390-3393
13. Sessler JL, Burrell AK 1992 Expanded porphyrins Topics Curr Chem 161: 177-273
14. Young SW, Qing F, Harriman A, et al. 1996 Gadolinium (III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI Proc Natl Acad Sci USA 93: 6610-6615
15. Sessler JL, Mody TD, Hemmi GW, et al. 1993 Gadolinium (III) texaphyrin: a novel MRI contrast agentJ Am Chem Soc 115: 10368-10369
16. Young SW, Sidhu MK, Qing F, et al. 1994 Preclinical evaluation of gadolinium (III) texaphyrin complex Inv Radiol 29: 330-338
17. Sessler JL, Miller RA 2000 Texaphyrins: New drugs with diverse clinical applications in radiation and photodynamic therapy Biochem Pharmacol 59:733-739
18. Haacke EM, Brown RW, Thompson MR, Venkatesan R 1999 Magnetic Resonance Imaging - Physical Principles and Sequences Design. John Wiley & Sons, Inc., New York, p 367-370
19. Sessler JL,Tvermoes NA, Guldi DM, et al. 1999 One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins J Phys Chem A 103: 787-794
20. Magda D, Lepp C, Gerasimchuk N, et al. 2001 Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen speciesInt J Radiat Oncol Biol Phys 51: 1025-1036
21. Xu S, Zakian K, Thaler H, et al. 2001 Effect of motexafin gadolinium on tumor metabolism and radiation sensitivityInt J Radiat Oncol Biol Phys 49: 1381-1390
22. Miller RA, Woodburn K, Qing F, et al. 1999 In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancerInt J Radiat Oncol Biol Phys 45: 981-989
23. Mehta MP, GiAs DR, Rockwell S, Thomas JP: Redox modulation: a novel approach to potentiate the effect of radiation therapy. A CME-certified symposium immediately preceding the 2001 annual meeting of ASTRO, San Francisco, November 3, 2001
24. Donnelly ET, Liu YF, Fatunmbi YO, et al. 2004 Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumorsInt J Radiat Oncol Biol Phys 58(5): 1570-1576
25. Mody TD, Fu L, Sessler JL 2001 Texaphyrins: Synthesis and development of a novel class of therapeutic agents In: Karlin KD, eds Progress in Inorganic Chemistry. John Wiley & Sons Inc, New York, pp. 551-598
26. Sessler JL, Mody TD, Hemmi GW, et al. 1993 Synthesis and structural characterization of Lanthanide(III) Texaphyrins Inorg Chem 32: 3175-3187
27. Sessler JL, Hemmi G, Mody TD, et al. 1994 Texaphyrins: Synthesis and applications Acc Chem Res 27: 43-50
28. Woodburn KW, 2001 Intracellular localization of the radiation enhancer Motexafin Gadolinium using interferometric Fourier fluorescence microscopy J Pharmacol Exp Ther 297: 888-894
29. Viala J, Vanel D, Meingan P, et al. 1999 Phases IB and II multidose trial of Gadolinium Texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases Radiology 212: 755-759
30. Mehta MP, Shapiro WR, Glantz MJ, et al. 2002 Lead-in phase to randomized trial of Motexafin Gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points J Clin Oncol 20: 3445-3453
31. Carde P, Timmerman R, Mehta MP, et al. 2001 Multicenter phase Ib/II trial of the radiation enhancer Motexafin gadolinium in patients with brain metastases J Clin Oncol 19: 2074-2083
32. Mehta MP, Rodrigus P, Terhaard CH, et al. 2003 Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases J Clin Oncol 21(13): 2529-2536
33. Meyers CA, Smith JA, Bezjak A, et al. 2004 Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial J Clin Oncol 22(1):157-165
34. Rosenthal DI, Nurenberg P, Becerra CR, et al. 1999 A Phase I single-dose trial of Gadolinium Texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging Clin Cancer Res 5: 739-745
35. Woods RP, Cherry SR, Mazziotta JC 1992 Rapid automated algorithm for aligning and reslicing PET images J Comput Assist Tomogr 16:620-633
36. Newman HF, Bleehen NM, Ward R, et al. 1988 Hypoxic cell radiosensitizers in the treatment of high grade gliomas: A new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)Int J Radiat Oncol Biol Phys 15: 677-684
37. Henry RG, Vigneron DB, Eischbein NJ, et al. 2000 Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas Am J Neuroradiol 21(2): 357-366
38. Manon R, Hui S, Chinnaiyan P, et al. 2004 The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme Technol Cancer Res Treat 3(3):303-307